ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington’s Disease — Active Not Recruiting • Phase I • NCT07246941.
- RG6496 is being tested in Huntington's disease gene carriers to assess its safety, tolerability, and how the body processes it.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 [single-ascending dose] followed by Part 2 [open-label extension (OLE)]. Conditions: Huntington's Disease Interventions: RG6496, Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 3 participants